The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
// Tengfei Zhang 1, 2, * , Jing Xie 3, * , Seiji Arai 2, 4 , Liping Wang 5 , Xuezhong Shi 6 , Ni Shi 7 , Fen Ma 2 , Sen Chen 2 , Lan Huang 1 , Li Yang 1 , Wang Ma 5 , Bin Zhang 8 , Weidong Han 9 , Jianchuan Xia 10 , Hu Chen 8 , Yi Zhang 1, 5, 11, 12 1 Biotherapy Center, Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China 2 Department of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States 3 School of Public Health, Xinxiang Medical University, Xinxiang, Henan, China 4 Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Japan 5 Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China 6 Department of Epidemiology and Biostatistics, School of Public Health, Zhengzhou University, Zhengzhou, Henan, China 7 Comprehensive Cancer Center, the Ohio State University, Columbus, Ohio, United States 8 Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital to Academy of Military Medical Science (307 Hospital, PLA), Beijing, China 9 Molecular and Immunological/Bio-therapeutic Department, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing China 10 Biotherapy Center, Cancer Center, Sun Yat-sen University, Guangzhou, Guangzhou, Guangdong, China 11 Henan Key Laboratory for Tumor Immunology and Biotherapy, Henan, China 12 School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China * These authors contributed equally to this work Correspondence to: Yi Zhang, email: yizhang@zzu.edu.cn Hu Chen, email: chenhu217@aliyun.com Keywords: PD-1, PD-L1, immunotherapy, advanced or refractory cancer, meta-analysis Received: May 27, 2016 Accepted: September 17, 2016 Published: September 24, 2016 ABSTRACT Purpose: To systematically evaluate the overall efficacy and safety of current anti-PD-1/PD-L1 antibodies for treatment of patients with advanced or refractory cancer. Results: Fifty-one trials including 6,800 patients were included. The overall response rates for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) were 29% (95% CI: 1.53−2.41), 21% (95% CI: 17%−25%) and 21% (95% CI: 16%−27%) respectively. While the overall adverse effects rate for melanoma, NSCLC, RCC were 16% (95% CI: 6%−28%), 11% (95% CI: 8%−14%) and 20% (95% CI: 11%−32%) respectively. Tumor PD-L1 expression and patient smoking status might serve as biomarkers to predict response of anti-PD-1/PD-L1 antibody treatment. Compared to tumors with negative PD-L1 expression, tumors with positive PD-L1 expression had a significantly higher clinical response rate (41.4% versus 26.5%) with RR = 1.92 (95% CI: 1.53−2.41, P < 0.001). Smoker patients also showed a significantly higher response rate (33.7%) than patients who never smoked (4.2%) with RR = 6.02 (95% CI: 1.22−29.75, P = 0.028). Nivolumab and Pembrolizumab were associated with significantly increased response rate (RR = 2.89, 95% CI: 2.46−3.40, P < 0.001), reduced death risk (HR= 0.53; 95% CI: 0.48−0.57; P < 0.001), and decreased adverse effect rate (RR = 0.49, 95% CI: 0.30−0.80, P = 0.004) compared with other therapies. Experimental Design: Clinical trials reporting response or safety of anti-PD-1/PD-L1 antibodies for advanced or refractory cancer patients published before January 31th 2016 were searched in PubMed and EMBASE database. Meta-analyses using random effects models were used to calculate the overall estimate. Conclusions: Anti-PD-1/PD-L1 antibodies have high response rates and low adverse effect rates for advanced or refractory cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slim, K., Nini, E., Forestier, D., Kwiatkowski, F., Panis, Y., & Chipponi, J. (2003) · ANZ Journal of Surgery · doi:10.1046/j.1445-2197.2003.02748.x · Cited by 7,603 · cited 3×
“Literature quality assessment by MINORS showed that literatures recruited in this study were in good quality (Supplementary Table S2).”
MethodInfluentialNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Ipilimumab, the first immune check point inhibitor targeted CTLA4, showed an objective response only 11% [24, 25].”
BackgroundWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“Blocking of PD-1 alone might not fully restore the function of antitumor T cells because of other inhibitory receptors such as CTL-4, LAG3, TIM3, BTLA, CD160, and CD244 [5, 14, 42].”
BackgroundCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 1×
“In addition, immune evasion by cancer cells that spoil the initiation of effective antitumor response in cancer microenvironment inevitably presents problems for treatment of advanced and refractory cancer patients [3, 4].”
BackgroundNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“PD-1 is normally required for limiting autoimmunity and modulating the strength of T cell response in peripheral infected tissues in order to minimize damage to surrounding normal tissues [5, 6].”
BackgroundMetaprop: a Stata command to perform meta-analysis of binomial data
Nyaga, V. N., Arbyn, M., & Aerts, M. (2014) · Archives of Public Health · doi:10.1186/2049-3258-72-39 · Cited by 2,139 · cited 1×
“Metaprop is a statistical program implemented to perform metaanalyses of proportions as mentioned in our former study [46, 47].”
MethodRobert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774 · cited 3×
“Similar adverse effects were reported in Pembrolizumab and Nivolumab [8, 40, 41].”
Background
Cited by
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
Voli, F., Valli, E., Lerra, L., Kimpton, K., Saletta, F., Giorgi, F. M., Mercatelli, D., Rouaen, J. R. C., Shen, S., Murray, J. E., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0471 · Cited by 411
Lau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161
Metadata
- Authors
- Zhang, T., Xie, J., Arai, S., Wang, L., Shi, X., Shi, N., Ma, F., Chen, S., Huang, L., Yang, L., Ma, W., Zhang, B., Han, W., Xia, J., Chen, H., & Zhang, Y.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-09-24
- Volume
- 7
- Issue
- 45
- Pages
- 73068-73079
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2522296004
- Cited by
- 91
- References
- 11
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. https://app.cochat.ai/papers/10.18632/oncotarget.12230
- The paper
- Zhang, T., Xie, J., Arai, S., Wang, L., Shi, X., Shi, N., Ma, F., Chen, S., Huang, L., Yang, L., Ma, W., Zhang, B., Han, W., Xia, J., Chen, H., & Zhang, Y. (2016). The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget. https://doi.org/10.18632/oncotarget.12230
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.